CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis
Disease activity fell in all six participants in a phase I trial, with three achieving sustained drug-free remission during follow-up
Clinical Scorecard: CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis
At a Glance
| Category | Detail |
|---|
| Condition | Rheumatoid Arthritis |
| Key Mechanisms | CD19-directed CAR T cell therapy targeting B cells |
| Target Population | Patients with severe, treatment-refractory rheumatoid arthritis |
| Care Setting | Clinical trial setting |
Key Highlights
- Single infusion of CD19 CAR T cells reduced disease activity in all participants
- Median reduction of disease activity scores was 49% at week 24
- Three participants maintained remission without medication for up to 52 weeks
- All participants experienced grade 1 or 2 cytokine release syndrome
- Study will proceed to randomized phase II stage comparing with rituximab
Guideline-Based Recommendations
Diagnosis
- Assessment of disease activity in rheumatoid arthritis
Management
- Consideration of CD19 CAR T therapy in treatment-refractory cases
Monitoring & Follow-up
- Monitoring for cytokine release syndrome and cytopenias post-infusion
Risks
- Potential for cytokine release syndrome and cytopenias
Patient & Prescribing Data
Adults aged 31-69 with longstanding seropositive rheumatoid arthritis
Prior treatment with multiple disease-modifying therapies
Clinical Best Practices
- Conduct thorough pre-treatment assessment for eligibility
- Monitor patients closely for adverse effects post-infusion
- Consider long-term follow-up to assess treatment effects on immunity
Related Resources & Content
